Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Zai Lab Limited

Market Cap 2.04B 35.37B 1.78B 1.65B 1.54B 2.9B 193B 2.91B 19.57B 7.58B 94.87B 7.67B 7.5B 329B P/E 2026 *
-8.21x
P/E 2027 * -9.75x
Enterprise Value 1.6B 27.7B 1.39B 1.29B 1.21B 2.27B 151B 2.28B 15.32B 5.94B 74.29B 6B 5.88B 258B EV / Sales 2026 *
3.56x
EV / Sales 2027 * 2.78x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
3 years 270.64
Extreme 270.64
810
5 years 270.64
Extreme 270.64
2,446.85
10 years 270.64
Extreme 270.64
3,693.35
Manager TitleAgeSince
Chief Executive Officer 60 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 60 01/04/2014
Director/Board Member 82 01/01/2017
Director/Board Member 74 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+43.36%-.--% - - 2.04B
-1.99%-2.38%+17.27%-23.01% 62.05B
-1.64%-5.25%+49.39%+193.99% 54.52B
-3.92%+37.40%+37.40%+37.40% 41.55B
-2.96%+6.96%-53.12%-59.97% 39.06B
+0.12%-1.02%+57.59%-33.11% 29.02B
-7.24%+13.65%+130.79%-50.83% 25.38B
+3.44%-0.43%+50.97%+64.02% 19.62B
-1.05%-2.65%-4.50%+147.45% 16.89B
+0.89%+2.39%+60.91%+111.29% 15.89B
Average +2.90%+2.77%+38.52%+43.03% 33.78B
Weighted average by Cap. -1.69%+1.72%+33.31%+38.24%

Financials

2026 *2027 *
Net sales 449M 7.77B 391M 362M 339M 636M 42.34B 640M 4.3B 1.67B 20.84B 1.68B 1.65B 72.36B 596M 10.31B 519M 481M 450M 844M 56.2B 849M 5.71B 2.21B 27.66B 2.24B 2.19B 96.05B
Net income -241M -4.17B -210M -195M -182M -342M -22.73B -344M -2.31B -894M -11.19B -904M -885M -38.85B -156M -2.71B -136M -126M -118M -222M -14.76B -223M -1.5B -581M -7.27B -587M -575M -25.23B
Net Debt -443M -7.67B -386M -358M -335M -628M -41.81B -632M -4.25B -1.65B -20.58B -1.66B -1.63B -71.46B -387M -6.7B -338M -313M -293M -549M -36.53B -552M -3.71B -1.44B -17.98B -1.45B -1.42B -62.44B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
18.18USD
Average target price
33.30USD
Spread / Average Target
+83.19%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!